Becaplermin rhPDGF Brand Name– Regranex
What is Becaplermin rhPDGF
Becaplermin rhPDGF BB is approved for use as a topical wound healing agent to treat lower extremity, neuropathic, diabetic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply.
The efficacy of becaplermin has not been established for diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue, for diabetic ischemic ulcers, for venous stasis ulcers, or for pressure ulcers.
The drug is a recombinant formulation of human platelet-derived growth factor (PDGF). Becaplermin is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds and is produced by insertion of the gene for the B chain of PDGF into the yeast,
Saccharomyces cerevisiae. Platelet-derived growth factor is a protein that is normally secreted by platelets, macrophages, endothelial cells, and, in some cases, fibroblasts.
Indications
- decubitus ulcer
- diabetic foot ulcer
- wound management
For the treatment of lower extremity diabetic neuropathic ulcers (e.g., diabetic foot ulcer) that extend into the subcutaneous tissue or beyond and have an adequate blood supply
Side Effects
- erythema
- new primary malignancy
- rash
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- children
- corticosteroid therapy
- infants
- infection
- mortality
- neonates
- neoplastic disease
- new primary malignancy
- peripheral vascular disease
- pregnancy
Interactions
There are no drug interactions associated with Becaplermin, rh-PDGF products.
